ENDRA Life Sciences Inc. (NDRA) stock
NDRANasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$4.04+0.12 (+2.93%)
Close on Nov 18, 2026Market cap $6.05MP/E –Yield –
Earnings
ENDRA Life Sciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q1 FY2025
–
EPS, Q1 FY2025
-$1.86
-$0.26 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of ENDRA Life Sciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | Aug 17, 2026after the close | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 31, 2026after the close | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 9, 2025after the close | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 15, 2025after the close | – | – | -$1.86 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 31, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 15, 2024after the close | – | – | -$9.54 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 23, 2024after the close | – | – | -$0.08 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 14, 2024after the close | – | – | -$0.26 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 28, 2024after the close | – | – | $0.17 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023after the close | – | – | -$0.40 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023after the close | – | – | -$0.43 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 15, 2023after the close | – | – | -$0.93 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 14, 2023after the close | – | – | -$1.04 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022after the close | – | – | -$0.05 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022after the close | – | – | -$0.06 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022after the close | – | – | -$0.07 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 30, 2022after the close | – | – | -$0.07 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 15, 2021after the close | – | – | -$0.06 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 27, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 25, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 16, 2020after the close | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 17, 2020after the close | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 14, 2020after the close | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 26, 2020after the close | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Nov 13, 2019after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
ENDRA Life Sciences has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When ENDRA Life Sciences puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases ENDRA Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Update
- Update
- Update
- Update
- Results
- Results
- Results
- Results
- Update
- Results
See a number that looks wrong?